Dimensional Fund Advisors’s BridgeBio Oncology BBOT Stock Holding History

Dimensional Fund Advisors’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$214K	Buy	+52,406	New	+$407K	﹤0.01%	3056

Other funds holding BBOT

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Regents of the University of California Oakland, California $6.64B AUM 23.46% 1-Year Est. Return

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

Dimensional Fund Advisors's BBOT Position: Q3 2026 in Review

Dimensional Fund Advisors opened a new position in BridgeBio Oncology (BBOT) in Q3 2026: 52,406 shares worth $214K. The stake represents ﹤0.01% of the portfolio and ranks #3056 among its holdings.

12 funds tracked by Wall St. Rank hold BBOT as of Q3 2026.

Dimensional Fund Advisors held 52,406 shares of BridgeBio Oncology worth $214K as of Q3 2026.
BridgeBio Oncology was a new Dimensional Fund Advisors position in Q3 2026.
BridgeBio Oncology made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #3056 holding.
12 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.